The currently ongoing CardiAMP Heart Failure trial has completed enrollment, and the final data analyses are anticipated to be reported in Q4 2024. 

In an interim analysis of available data to date for study patients followed up through two years, those having N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels consistent as demarcating heart failure (>500 pg/ml) at screening baseline showed meaningful clinical improvements over controls, including a 59% relative risk reduction in heart death and a 54% relative risk reduction of Major Adverse Cardiovascular or Cerebrovascular events (MACCE). 

The FDA has approved the proposed CardiAMP Heart Failure II study, which includes an eligibility requirement that patients demonstrate a pre-specified NT-proBNP level at baseline. 

Price Action: BCDA shares are up 225.70% at $1.30 on the last check Tuesday.